Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.45 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | HTR7 | P34969 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 2/20 | 0.35 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.35 |
| ▸ | FURIN | P09958 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897841 | 0.94 | HDAC8 (0.43) | HDAC8HTR1AHTR7PKMALDH1A1 | |
| SCHEMBL1744910 | 0.88 | HDAC8 (0.51) | HDAC8HTR1AHTR7PKMALDH1A1 | |
| SCHEMBL557991 | 0.87 | HDAC8 (0.35) | HDAC8HTR1AHTR7ALDH1A1KDM4E | |
| SCHEMBL557519 | 0.82 | HDAC8 (0.51) | HDAC8HTR1AHTR7GAAHTT | |
| SCHEMBL2927183 | 0.82 | HSD17B10 (0.42) | HDAC8HTR1AHTR7PKMALDH1A1 | |
| SCHEMBL557953 | 0.82 | HSD17B10 (0.42) | HDAC8HTR1AHTR7PKMALDH1A1 | |
| SCHEMBL556503 | 0.81 | HDAC8 (0.36) | HDAC8 | |
| SCHEMBL11914021 | 0.80 | HTR1A (0.49) | HDAC8HTR1AHTR7ALDH1A1MAPT | |
| SCHEMBL15061945 | 0.80 | HDAC8 (0.41) | HDAC8HTR1AHTR7PKMALDH1A1 | |
| SCHEMBL558129 | 0.79 | HDAC8 (0.40) | HDAC8HTR1AHTR7PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46170-E1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2016-10-04 | — | — | US | disclosed |
| US-8722620-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2014-05-13 | — | — | US | disclosed |
| EP-2256130-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2013-09-25 | — | — | EP | disclosed |
| US-8476228-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2013-07-02 | — | — | US | disclosed |
| EP-1846446-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2013-06-26 | — | — | EP | disclosed |
| US-20120035104-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-02-09 | — | — | US | disclosed |
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | disclosed |
| EP-2256130-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| EP-2256129-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| EP-1991576-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2010-09-29 | — | — | EP | disclosed |
| US-20090137454-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137454-A1 | Insulin Derivatives | IAPP, INSR, GPR119 | HDAC8 2197/4885HTR1A 3311/4885HTR7 2622/4885 |
| US-20120035104-A1 | Insulin derivatives | IAPP, INSR, GPR119 | HDAC8 1374/4885HTR1A 3864/4885HTR7 2753/4885 |
| US-20080076705-A1 | Insulin Derivatives | IAPP, INSR, GPR119 | HDAC8 1287/4885HTR1A 4178/4885HTR7 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.